-
Tips for becoming a good boxer - November 6, 2020
-
7 expert tips for making your hens night a memorable one - November 6, 2020
-
5 reasons to host your Christmas party on a cruise boat - November 6, 2020
-
What to do when you’re charged with a crime - November 6, 2020
-
Should you get one or multiple dogs? Here’s all you need to know - November 3, 2020
-
A Guide: How to Build Your Very Own Magic Mirror - February 14, 2019
-
Our Top Inspirational Baseball Stars - November 24, 2018
-
Five Tech Tools That Will Help You Turn Your Blog into a Business - November 24, 2018
-
How to Indulge on Vacation without Expanding Your Waist - November 9, 2018
-
5 Strategies for Businesses to Appeal to Today’s Increasingly Mobile-Crazed Customers - November 9, 2018
Abbott posts 9M profit jump as nutrition sales up
The company recorded a negative impact of 9.5% due to currency exchange.
Advertisement
Excluding items, Abbott earned 54 cents per share. Earnings, adjusted for one-time gains and costs, came to 43 cents per share.
Abbott Labs’ market cap is now $62.21B and has a P/E ratio of 14.
According to the analysts polled by Zack’s Research, Abbott Laboratories (NYSE:ABT) has been given a one year consensus price target range of $53 to $58.
Meanwhile, the company cut its guidance for motorcycle shipments for the year to between 265,000 and 270,000 from prior guidance of between 276,000 and 281,000.
As of this writing, shares of Abbott Laboratories were down 0.36% at $41.60 per share in premarket trades. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock.
If we break down the analyst ratings into a simplified scale, Abbott Laboratories (NYSE:ABT) has a Buy-Sell rating of 1.85.
Furthermore, the company generated revenue of $2.77 billion, beating the consensus estimate of $2.63 billion by 5.29%.
Historically, Abbott Labs has been trading with a 52 week low of 39.00 and a 52 week of high 51.74. Analysts predict that Abbott Laboratories will post $2.16 EPS for the current year. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Can Abbott Laboratories turn tables following this earnings announcement? The stock ended up at $42.22.
The stock has a 50 day moving average of $42.11 and a 200-day moving average of $46.93.
Revenue increased 1.4%, to $5.2 billion from $5.08 billion for the year ago period, ahead of analysts’ estimated $5.14 billion for the most recent quarter. Sales in key emerging markets climbed 37.1% on an operational basis driven by growth in India, Russia, Brazil, China, and certain markets in Latin America.
Abbott Laboratories (NYSE:ABT): The mean short term price target for Abbott Laboratories (NYSE:ABT) has been established at $52.85 per share.
The company also recently announced a quarterly dividend, which will be paid on Sunday, November 15th. Transocean Ltd. (RIG) is trading at $15.340, with a weekly performance of – 0.580% and gross margin of 53.70%. This represents a $0.96 dividend on an annualized basis and a yield of 2.27%. The ex-dividend date of this dividend is Tuesday, October 13th.
Abbott Laboratories (NYSE:ABT) is engaged in the discovery, development, production and sale of a range of healthcare products.
Advertisement
Revenue from its nutritional products business, its largest, rose 6.5 percent. The Created Pharmaceutical Products segment includes the global deal of a line of pharmaceutical products that are generic that are branded.